ANAVEX LIFE SCIENCES CORP.
Nasdaq · CIK 0001314052 · Fiscal year end 0930
Latest reported period: Latest published period
Operating Income
$-6.8M
Net Income
$-5.7M
Eps Basic
-0.06
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-6.8M | - | - |
| Net Income | $-5.7M | - | - |
| Eps Basic | -0.06 | - | - |
| Eps Diluted | -0.06 | - | - |
| Cash And Equivalents | $131.7M | - | - |
| Total Assets | $133.0M | - | - |
| Total Liabilities | $6.4M | - | - |
| Shareholders Equity | $126.6M | - | - |
| Operating Cash Flow | $-7.2M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | ANAVEX LIFE SCIENCES CORP. | 2026-02-09 | 0001731122-26-000200 |
| 10-K | ANAVEX LIFE SCIENCES CORP. | 2025-11-25 | 0001731122-25-001596 |
| 4 | ANAVEX LIFE SCIENCES CORP. | 2025-09-12 | 0001731122-25-001246 |
| 10-Q | ANAVEX LIFE SCIENCES CORP. | 2025-08-12 | 0001731122-25-001105 |